
Lisa Boothe ๐บ๐ธ @LisaMarieBoothe
@DebunkJunction @BMeiselas Because Merck doesnโt have a patent on ivermectin and it is incredibly cheap to make. However, Merck has a $1.2 billion contact with the U.S. government for this new therapeutic which costs $700 per patient. https://t.co/oxOHtwpl83 — PolitiTweet.org